FORM PTO-1449 (modified) To: U.S. Department of Commerce (PW FORM PAT-1449) Patent and Trademark Office									Atty. Dkt. No.	M#	M#		Clie	Client Ref.			
INFORMATION DISCLOSURE STATEMENT								037003-0275823 Applicant: Noelle				1995-30-0232C2					
BY A	BY APPLICANT									Apple No : 00/222 524							
									Appln. No.: 09/223,634								
						٦.,		1	Filing Date: December 3					4044	4044.4		
				Pag e	1	of	2		Examine	r: 	: Gambel, P.		up Art Unit:		1644		
U.S.	PATE	NT C	OCUMENTS								and the second s						
Examiner Document Number				Date MM/YYYY		Name (Family Name of First Inventor)		Class	Ss Sub Class		Filing Date (if appropriate)						
Initia		AD	4 040 207	-	02/400		Dana at					425	- -		(ii approp	niato)	
		AR	4,816,397		03/198		Boss, et		-			435	68	387			
-		BR	4,816,567		03/198		Cabilly, e					530			+		
\dashv		CR DR	5,116,964		05/199	۷	Capon, e	t al.				536	27		-		
	Contract.		I ENT DOCUMENTS	1. Sept.		× 1000 L	A CONTRACT			n grape	5-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1		English		Translat	****	
F.⊕rk	EIGN	BAII	Document Number	Date		T	ountry	T	ntor Name		u 1-4-50	1.1	Abstrac	_,	Readily Available Enclose	le	
		ER	0 171 496 B1	05/1	993	EF)	Tani	guchi, et a	ıl.						丁	
		FR	0 173 494 A2		986	EF			rison, et al.				_	_	-	+ 1	
		GR	0 239 400 B1		994	EF	,	1	ter, et al.				J	_		-	
		HR	0 194 276 A1	03/1	986	EF	•	1	berger, et a	al.				-		\perp	
		IR	0 555 880 A2, A3	08/1	993	EF	•	7	fo, et al.				J	+-	_	+	
		JR	2 177 096 A	03/1	3/1986 GE		3	Neuberger, et a		al.				+-			
		KR	WO 92/06193			W	WO Go		rman, et al. Ierman, et al.								
		LR	WO 93/09812			W											
		MR	WO 94/28912	12/1	994	W	0	Tho	mpson, et a	al.						+	
		NR	WO 95/06481	03/1	995	W	0	Noe	lle, et al.							T	
		OR	WO 95/06666	03/1	995	W	0	Noe	lle, et al.								
ОТН	ER (Ir	ncludi	ng in this order Au	thor,	Title, Po	erio	dical Name	e, Dat	e, Pertiner	nt Pa	ages, etc.)						
		PR	Armitage, R.J., et 357:80—82 (1992		Molecula	ır ar	nd biologia	l char	acterizatio	n of	a murine Natu	ıre,					
		QR		I., The rapid isolation of clonable antigen-specific T lymphocyte mediating autoimmune encephalomyelitis, Eur J. Immunol. 11,										!			
		RR	Capon, D.J., et al. 525—531 (1989)	D.J., et al. Designing CD4 immunoadhesins for AIDS therapy, Nature 337, I (1989)													
		SR	Dautigny, A., et al., Molecular cloning and nucleotide sequence of a cDNA clone coding for rat brain myelin proteolipid, FEBS Lett. 188(1):33-36 (1985)														
		TR	Durie, F.H., et al., The role of CD40 and its ligand (gp39) in peripheral and central tolerance and its contribution to autoimmune disease, Research in Immunology, 145(3), 200-205 & 244-249 (1994)														
		UR	Durie, F.H., et al., Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40, Science, 261:1328-1330 (1993)														
		VR	Gerritse, K., t al., encephalomyelitis (1996)									2504					
E		WR	Hafler, D.A., et al.														

protein epitopes in the therapy of multiples (1991)

PHULLI GRUPS 10/12/2 3

No	XR	Hollenbaugh, D., et a he human T cell antigen gp3 family, is a ligand for the CD40 receptor: expression of B cell co-stimulatory activity, The EMBO J., 11(12):43	of a soluble form or gp39 with	
	YR	Karpus, W.J., et al., CD4+ suppressor cells differentia IFN-γ by effector cells of experimental autoimmune er 143:3492-3497 (1989)	ally affect th production of	
	ZR	Laman, J., et al., The role of gp39 (CD40 ligand) in E. Neuroimmunology, 54(1-2):175 (1994)	AE and MS, Journal of	
	AAR	Lederman, S., et al., Identification of a novel surfac page 13 cells that induces contact-dependent B cell differentian 175:1091—1101 (1992)		
	BBR	Lider, O., et al., Suppression of experimental autoimn oral administration of myelin basic protein, J. Immuno		
	CCR	Linsley, P.S., et al., Binding of the B cell activation and costimulates T cell proliferation and interleukin 2 mRN Med., 1783:721—730 (1991)		
	DDR	McCafferty, J., et al., Phage antibodies: filamentous p variable domains, Nature, 348:552—554 (1990)	hage displaying antibody	
	EER	Miller, A., et al., Antigen-driven bystander suppression antigens, J. Exp. Med. 174:791-798 (1991)	n after oral administration of	
	FFR	Mokhtarion, F., et al., Adoptive transfer of myelin basi produces chronic relapsing demyelinating disease in (1984)		
	GGR	Morrison, S., et al., Chimeric human antibody molecul domains with human constant region domains, Proc. 81:6851-6855 (1985)		
	HHR	Noelle, R.J., et al., A 39-kDa protein on activated help transduces the signal for cognate activation of B cells 89:6550-6554 (1992)		
	IIR	Olsson, L., et al., Human-human monoclonal antibody technical aspects, Meth, Enzymol., 92:3—17 (1982)	y-producing hybridomas:	
	JJR	Pesoa, S.A., et al., Regulation of experimental allergic Role of the recepient in suppressor cell induction, J. N (1984)		
		Pettinelli, C.B., et al., Adoptive transfer of experiments SJL/J mice after <i>in vitro</i> activation of lymph node cells requirement for Lyt 1 ⁺ 2 ⁻ T lymphocytes, J. Immunol.	by myelin basic protein:	
	LLR	Sobel, R.A., et al., Acute experimental allergic encept induced by a synthetic peptide of myelin proteolipid pr Neurol. 49(5):468-479 (1990)		
	MMF	Stamenkovic, I., et al., A B-lymphocyte activation mole growth factor receptor and induced by cytokines in ca 8(5),1403—1410 (1989)		
	NNR	Takeda S., et al., Construction of chimaeric processes containing mouse variable and human constant region 314(4):452-454 (1985)		
	OOR	Teng, N. et al., Construction and testing of mouse-hull human monoclonal antibody production, Proc. Natl. A 7312 (1983)		
	PPR	Tuohy, V.K., et al., Identification of an encephalitogen proteolipid protein for SJL mice, J. Immunol. 142:152:		
	QQR	van der Veen, R. et al., The adoptive transfer of chror allergic encephalomyelitis with lymph node cells sensi protein, J. Neuroimmunol. 21:183-191 (1989)	nic relapsing experimental	
/	RRR	Ward, E.S., et al., Binding activities of a repertoire of svariabl domains s creted from Escherichia coli, Natu		
miner	Dun		te Considered:	

PAT-1449 12/98